Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers

BioDrugs

Volumn 16, Issue 1, 2002, Pages 63-70

  Allison, D E ^a   Gourlay, S G ^a   Koren, E ^a   Miller, R M ^b   Fox, J A ^a  

^a GENENTECH INC   (United States)

^b Fulcrum Pharma Developments Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; CD18 ANTIGEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTEGRIN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY CD18; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPERFUSION INJURY; SINGLE BLIND PROCEDURE;

EID: 0036222797     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216010-00007     Document Type: Article

References (19)

1. The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: Their quantitative definition and relation to leukocyte dysfunction and clinical features
2. Psoriasis is clinically and histologically improved by treatment with a humanized anti-CD11a monoclonal antibody (hu1124): Results of a multicenter, multiple ascending dose study
3. The I domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands
4. Activated human platelets express b2 integrin
5. Platelet glycoprotein ibalpha is a counterreceptor for the leukocyte integrin Mac-1 (CD11b/CD18)
6. An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion
7. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion
8. Ischemia reperfusion injury in the rabbit ear is reduced by both immediate and delayed CD18 leukocyte adherence blockade
9. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mo1, anti-CD11b) that inhibits leukocyte adhesion
10. A double-blind, randomized trial of anti-CD18 antibody in conjunction with rtPA for acute myocardial infarction: The LIMIT AMI study
11. HALT MI (HU23F2G Anti-adhesion to limit cytotoxic injury following acute MI). Highlights of the 72nd Scientific Sessions of the American Heart Association; 1999 Nov 7-10; Atlanta (GA)
12. Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: Results of a phase II clinical trial
13. Monoclonal antibodies against porcine LFA-1: Species cross-reactivity and functional effects of beta-subunit-specific antibodies
14. Cardioprotective actions of a monoclonal antibody against CD18 in myocardial ischemia-reperfusion injury
15. Role of neutrophils in ischemia-reperfusion-induced microvascular injury
16. Abnormally short serum half-lives of IgG in β2-microblobulin-deficient mice
17. Antibodies and their receptors
18. OKT3 F(ab′)2 fragments - Retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release